Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Next Previous
X
Search
Drug Profile

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Alternative Names: 4-Hydroxy-N-desmethyltamoxifen; Z-endoxifen; Z-Endoxifen Hydrochloride

Latest Information Update: 01 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals; Jina Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Methylamines; Phenyl ethers; Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders
  • Phase II Breast cancer
  • No development reported Fibroma; Gynaecological cancer

Most Recent Events

  • 19 Mar 2024 Jina Pharmaceuticals initiates enrolment in phase III trial in Bipolar disorders (Treatment-experienced) in USA (PO) (NCT06608641)
  • 28 Nov 2021 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Neoadjuvant therapy) in USA (Topical, Gel)
  • 13 Sep 2021 Pharmacokinetics data from two phase I clinical trials presented at the 2021 American College of Clinical Pharmacology Annual Meeting (ACCP-2021) by National Cancer Institute

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top